MedTrace Logo

Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain

NCT06827262 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1500

Last updated 2026-05-18

No results posted yet for this study

Summary

Compile real-world outcomes of commercially approved Intracept™ Intraosseous Nerve Ablation Systems in the treatment of patients diagnosed with vertebrogenic pain.

Conditions

  • Chronic Low-back Pain
  • Vertebrogenic Pain Syndrome

Interventions

DEVICE

Intracept™ Intraosseous Nerve Ablation

Intracept™ Intraosseous Nerve Ablation for treatment of patients diagnosed with vertebrogenic pain

Sponsors & Collaborators

  • Boston Scientific Corporation

    lead INDUSTRY

Principal Investigators

  • Natalie Bloom Lyons, M.A. · Boston Scientific Corporation

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-26
Primary Completion
2034-07-31
Completion
2034-07-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06827262 on ClinicalTrials.gov